ERBB2 and neoplasm: Since it has been shown that the tumor uptake of classically labeled [111In]In-trastuzumab (i.e., radiometal-chelate-antibody constructs) depends on HER2 density expression, our values are slightly different but still in the expected range (McLarty et al. 2009).